Phase 1 Open Label Safety, Acceptability, Pharmacokinetic and ex Vivo Pharmacodynamic Study of TMC278 Long Acting (LA) Administered Intramuscularly to HIV-1 Seronegative Individuals.
Phase of Trial: Phase I
Latest Information Update: 22 Jul 2016
At a glance
- Drugs Rilpivirine (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Janssen Research & Development
- 06 Apr 2016 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
- 11 Feb 2016 Planned End Date changed from 1 Dec 2015 to 1 Feb 2016 as reported by ClinicalTrials.gov .
- 31 Mar 2014 Planned End Date changed from 1 Apr 2014 to 1 Dec 2015, as per ClinicalTrials.gov record.